Open | $3.510 |
Close | $3.520 |
Volume / Avg. | 2.102K / 21.145K |
Day Range | 3.460 - 3.520 |
52 Wk Range | 2.894 - 4.750 |
Market Cap | $177.911M |
P/E Ratio | - |
Dividend Yield | - |
Exchange | NASDAQ |
RSI | 43 |
Short Interest | 0.19% |
Days to Cover | 9.65 |
Name |
---|
Revenue Change |
Gross Change |
EBITDA Change |
EBIT Change |
Earnings Change |
You can purchase shares of Genfit (NASDAQ: GNFT) through any online brokerage.
Other companies in Genfit’s space includes: Syros Pharmaceuticals (NASDAQ:SYRS), Graphite Bio (NASDAQ:GRPH), Innate Pharma (NASDAQ:IPHA), Atossa Therapeutics (NASDAQ:ATOS) and FibroGen (NASDAQ:FGEN).
The latest price target for Genfit (NASDAQ: GNFT) was reported by HC Wainwright & Co. on Friday, December 8, 2023. The analyst firm set a price target for 11.00 expecting GNFT to rise to within 12 months (a possible 208.12% upside). 6 analyst firms have reported ratings in the last year.
The stock price for Genfit (NASDAQ: GNFT) is $3.57 last updated March 12, 2024 at 4:57 AM EDT.
There are no upcoming dividends for Genfit.
Genfit’s FY earnings are confirmed for Thursday, April 4, 2024.
There is no upcoming split for Genfit.
Genfit is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.